Growth calculators to help you assess patients’ growth
Evaluate various aspects of your patients’ growth with these calculators. To get started, log in to your novoMEDLINKTM account, or create an account today.
Actor portrayal
Growth calculators to help you assess patients’ growth
Actor portrayal
Evaluate various aspects of your patients’ growth with these calculators. To get started, log in to your novoMEDLINKTM account, or create an account today.
Height velocity calculator
Gauge patients’ growth rate over time.
Target height calculator
Estimate midparental target height.
Body mass index calculator
Compute body mass index (BMI) for your patients.
Body surface area calculator
Figure your patients’ body surface area.
Sogroya® is now approved for additional indications for pediatric patients aged 2.5 years and older with: short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, growth failure associated with Noonan Syndrome (NS), and Idiopathic Short Stature (ISS). Read the press release.
Discover a once-weekly growth hormone treatment
Sogroya® is the first and only once-weekly growth hormone treatment approved for GHD and 3 other specific pediatric growth-related conditions.
Sogroya® is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) and for the treatment of pediatric patients aged 2.5 years and older with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, growth failure associated with Noonan Syndrome (NS), and Idiopathic Short Stature (ISS). Please see full indications.
Important Safety Information
Contraindications
Sogroya® is contraindicated in patients with:
acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya® hypersensitivity to Sogroya® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin pediatric patients with closed epiphyses active malignancy active proliferative or severe non-proliferative diabetic retinopathy pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death
Important Safety Information Continued
Please see Sogroya® Prescribing Information.
Explore our once-daily growth hormone treatment
Norditropin® is the only daily growth hormone therapy approved for 7 indications.
Norditropin® is indicated for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH) and Prader-Willi Syndrome; short stature associated with Noonan Syndrome, Turner Syndrome, and children born small for gestational age; idiopathic short stature; and for the replacement of endogenous GH in adults with growth hormone deficiency (GHD). Please see full indications.